Sagility Limited Board Approves New Employee Stock Option and Performance Unit Scheme 2026

Sagility Limited has announced the approval of its Employee Stock Options and Performance Stock Units Scheme 2026. The board has cleared a total pool of over 15.45 crore shares, representing 3.30% of the company’s current paid-up capital, to be offered to eligible directors and employees. This initiative is designed to incentivize performance and align long-term growth objectives with the company’s workforce, subject to final shareholder approval via postal ballot.

Incentivizing Future Growth

The company has introduced the ESOS 2026 program to foster long-term value creation among its leadership and staff. By utilizing both Employee Stock Options and Performance Stock Units (PSUs), Sagility aims to retain top talent and drive operational excellence. The total allocation includes 3,09,10,845 stock options and 12,36,43,222 performance units, with each instrument convertible into one fully paid-up equity share of ₹10 face value.

Strategic Allocation Details

The total equity pool reserved for this scheme stands at 15,45,54,067 shares. Under the defined pricing formula, the exercise price for stock options will be set at or above the market price on the grant date, while PSUs will be granted at face value. The scheme underscores the firm’s commitment to employee ownership, with vesting and exercise periods structured to encourage sustained commitment to company milestones over the coming years.

Shareholder Approval Process

As the next step in the implementation process, the company will seek formal authorization from shareholders. This approval will be conducted through a postal ballot process. Once finalized, the specific terms, including vesting conditions and performance metrics, will be detailed in the upcoming explanatory statement provided to shareholders, ensuring transparency as the company moves forward with its new reward framework.

Source: BSE

Previous Article

INOX India Reports Record-Breaking Q4 and Annual Financial Performance for FY26

Next Article

Pfizer Limited Audited Annual Results and Dividend Announcement for FY2026